What Espididol Treats: Main Uses and Benefits

The active ingredient in Espididol, Ibuprofen Lysinate, is commonly used to help with symptoms related to physical discomfort and systemic imbalance. Its therapeutic scope is relevant when supportive symptom management is appropriate for acute episodes.

The medication is commonly used across conditions presenting with acute episodes and provides support that helps ease the overall symptom burden. It is applied in addressing mild to moderate painful discomfort, including headaches, dental pain, back pain (lumbago), muscle aches, and is relevant for the management of feverish states and painful menstrual periods (dysmenorrhea). This action assists with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Acute and Episodic Symptoms

Espididol is relevant in clinical settings that involve acute or unstable symptom patterns, supporting management across three key symptom domains: it helps ease musculoskeletal and headache pain, assists with the management of elevated body temperature, and contributes to improved comfort during periods of localized inflammation.

Regulatory References

1. Summary of Product Characteristics (SmPC)

The eligibility profile for Espididol (Ibuprofen Lysinate) is defined by regulatory authorities based on specific patient risk factors and physiological states, establishing clear boundaries for its use. The medicine is primarily intended for use in adults and adolescents weighing 40 kg or more.

Absolute Contraindications (Must Not Use)

Use is contraindicated and strictly prohibited for certain populations, including:

• Patients with known hypersensitivity to Ibuprofen, Acetylsalicylic acid (Aspirin), or other NSAIDs (due to risks like asthma or angioedema).
• Individuals with severe failure of the heart (NYHA Class IV), kidneys, or liver.
• Those with active or a history of recurrent peptic ulcers, gastrointestinal hemorrhage, or active internal bleeding.
• Women in the third trimester of pregnancy.
• Patients with severe dehydration or unclarified blood-formation disturbances.

Age and Conditional Use

• The oral formulation is not intended for use in children under 12 years of age or adolescents weighing less than 40 kg.
• In the first and second trimesters of pregnancy, use is not recommended unless clearly necessary, and must be restricted to the lowest effective dose for the shortest duration.
• Elderly patients require particular caution, as regulatory documents note an increased risk of adverse reactions, particularly gastrointestinal bleeding.
• Conditional use is applied to patients with moderate organ impairment, uncontrolled hypertension, or certain pre-existing conditions like Systemic Lupus Erythematosus (SLE) or a history of Crohn's disease.

Interactions with Other Medicines and Products

The information below summarizes the official interaction profile for Espididol (Ibuprofen Lysinate), strictly based on governmental regulatory documents.

Regulatory Interaction Classifications

Interaction Type	Examples of Interacting Medicines	Interaction-Related Restrictions
Contraindicated Combinations	Other NSAIDs (including COX-2 inhibitors), Anticoagulants (e.g., Warfarin), Methotrexate ( dose > 15 mg/week)	Prohibited co-administration due to officially documented severe risks (e.g., bleeding/ulceration).
Exposure-Modifying	Lithium, Digoxin, Phenytoin, CYP2C9 Inhibitors (e.g., Voriconazole, Fluconazole)	Co-administration may increase plasma levels of Ibuprofen or the co-administered drug, as clearance is reduced or inhibited.
Additive Risk	Corticosteroids, SSRIs, Diuretics, Antihypertensives	Pharmacodynamic effects are officially noted to increase the risk of serious gastrointestinal bleeding or acute renal dysfunction.

Official Timing and Population Rules

Specific regulatory constraints dictate how certain substances must be used alongside Ibuprofen Lysinate:

• Mandatory Time Separation: NSAIDs must not be administered for a period of 8 to 12 days following the use of Mifepristone due to the risk of reducing Mifepristone's effect. Similarly, low-dose Aspirin (antiplatelet use) requires a time separation to maintain its antiplatelet effect.
• Alcohol: Regulatory documents explicitly state that consumption of alcohol increases the risk of gastrointestinal bleeding when using this medicine.
• Elderly Population: Official labeling notes that elderly patients are at a higher risk of severe adverse effects, particularly gastrointestinal bleeding and renal issues, when combining Ibuprofen Lysinate with specific interacting drugs like Antihypertensives or Diuretics.

Molecular Inhibition of the Cyclooxygenase Pathway

The core mechanism of the active ingredient, Ibuprofen, involves the reversible, competitive inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This action blocks the Arachidonic Acid Cascade, thereby suppressing the synthesis of prostaglandins—lipid mediators that contribute to nociceptor sensitization and vascular responses. This molecular event modulates prostaglandin-mediated signal transmission to the central nervous system.

Modulation of Thermoregulation and Nociceptor Signaling

The mechanism results in critical physiological adjustments across central and peripheral systems. Peripherally, the reduction in prostaglandin synthesis reduces the sensitization of nociceptors (pain-sensing nerves) at sites of tissue damage. Centrally, the action occurs within the hypothalamus, where the medicine lowers the elevated thermoregulatory set-point, initiating processes to promote heat dissipation.

Formulation Mechanism for Accelerated Onset

Ibuprofen is formulated with L-Lysine to create a highly soluble salt. This chemical structure functions as a mechanism to significantly enhance the dissolution rate and accelerate the active molecule’s absorption into the systemic circulation. This process shortens the latency required for the molecule to achieve concentrations necessary to initiate the primary mechanism of enzyme inhibition.

How Espididol is Used: Official Administration Guidelines

Espididol, containing Ibuprofen Lysinate, is intended for strictly oral administration and is approved for short-term use only. The official usage protocol dictates precise dosing quantities, frequency, and duration limits that must be adhered to, as established by medical and health authorities.

---

Dosing and Scheduling

The standard protocol for adults and adolescents weighing 40 kg or more involves an initial dose between 200 mg and 400 mg of Ibuprofen equivalent. The dose may be repeated, but administrations must be separated by a minimum interval of 6 hours. The maximal daily dose is strictly limited and must not exceed 1200 mg in any 24-hour period. The medication is for limited use, generally restricted to 3 days for fever and 5 days for pain management.

---

Administration Requirements

Requirement	Instructions
Route & Form	Oral use via film-coated tablets or granules for oral solution.
Preparation	Tablets must be swallowed whole with water; granules must be fully dissolved in a glass of water before consumption.
Meal Timing	Administration is recommended with food if the user has a sensitive stomach, although this may delay the onset of action.
Population Rule	The medicine is not intended for use in children under 12 years of age or adolescents below 40 kg body weight.

These guidelines define the complete framework for how the medicine must be taken and ensure adherence to label constraints.

Research Evidence / Overview of Studies for Espididol

Evidence for Acute Pain and General Use

The research examining Ibuprofen Lysinate (Espididol’s active ingredient) for acute pain response has largely centered on Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These studies evaluated outcomes related to physical discomfort over short, defined time intervals in healthy adult participants, such as following minor surgical procedures. Research describes patterns related to the timing of the observed analgesic effect, often compared against standard ibuprofen formulations.

For fever response and painful menstrual period response, evidence is primarily established through alignment with the broader therapeutic use of the parent drug, Ibuprofen, and supporting pharmacokinetic (PK) studies. PK research has explored the medicine’s absorption characteristics, with data showing patterns related to a differential rate of absorption compared to standard Ibuprofen acid in those studies.

---

Limitations and Knowledge Gaps

The evidence base for the oral formulation of Ibuprofen Lysinate is characterized by limitations common to acute relief treatments. The main efficacy research remains focused on a single model of acute pain and includes follow-up durations limited to single-dose measurements. Long-term effects and patterns from chronic administration are not fully established.

Furthermore, data for certain subgroups remain insufficient. Research in specific populations, such as older adults (geriatric patients) or those with multiple existing conditions, has not yielded extensive published data. Similarly, evidence for children is still emerging or pending, and the results primarily reflect the healthy adult populations studied in the acute pain trials.

Common questions about Espididol (FAQ)

---

Q: How long will I need to take Espididol?

A: The typical course of treatment for most patients taking this medication is 12 weeks. For some individuals, such as those with certain types of cirrhosis or who have previously failed other treatments, the healthcare provider may determine that a longer course of up to 24 weeks is appropriate. The full course of treatment, as prescribed by your healthcare provider, is strongly recommended. Regulatory information suggests that discontinuing treatment prematurely may reduce the chance of achieving a successful therapeutic response.

---

Q: What should I do if I miss a dose?

A: The product label typically provides guidance for handling a missed dose. Generally, if you remember the dose on the same day, you may take it. If a whole day has passed, it is usually recommended to skip the missed dose entirely and just take the next scheduled dose. Patients should not take two doses at the same time to make up for a missed dose. It is always best to consult with a healthcare professional or pharmacist regarding any missed doses or if you have questions about the dosing schedule.

---

Q: Can Espididol resolve my condition?

A: Espididol has demonstrated high efficacy in clinical trials for treating the indicated condition. The goal of treatment is to achieve a Sustained Therapeutic Response, which is defined as the condition remaining stable or resolved 12 weeks after the end of treatment. Achieving this response is generally understood to mean the therapeutic goal is met. However, treatment success is not guaranteed for every individual, and patients should discuss their prognosis with their healthcare provider.

---

Q: Is Espididol safe to take with other medications?

A: Espididol is known to have significant drug-drug interaction potential. The drug label contraindicates use with certain medications, such as St. John’s Wort, carbamazepine, and specific cholesterol-lowering drugs, due to the risk of serious side effects or reduced drug effectiveness. Patients are advised to fully inform their healthcare provider of all prescription and non-prescription medications, herbal products, and supplements they are taking to ensure a thorough review before starting Espididol.

The storage and disposal of Espididol (Ibuprofen Lysinate) are governed by specific regulatory requirements to maintain product stability and protect the environment.

Official Storage Requirements

Classification	Requirement
Temperature	Store below 30 C.
Protection	Keep in the original package to protect from moisture and light.
Child Safety	Must be kept out of the sight and reach of children.

Official Disposal Rules

Disposal must comply with environmental regulations:

• Do not dispose of any unused or expired medicine via wastewater or household waste.
• The product must be returned to a pharmacist or collected according to local requirements for proper pharmaceutical waste management.